DiabetesWRAP: Focus on
1,5-Anhydroglucitol (AG) for
Monitoring and Clinical Management
of Patients with Diabetes

HealthWRAP CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Release Date:

June 1, 2008

Expiration Date:

June 1, 2010

Intended Audience:

This program is designed for all practitioners with the following specialties or subspecialties: primary care physicians, internists, family medicine specialists, women’s health specialists, nephrologists, diabetes specialists, cardiologists, and other healthcare professionals managing diabetic patients.

Registration:

Enrollment for this HealthWRAP is complimentary, and clinicians are invited to participate in this CME-certified HealthWRAPs and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

Supported by an independent educational grant
from Quest Diagnostics

Accreditation Statement for Jointly-Sponsored Programs:

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Massachusetts Medical School designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty and Provider Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty:

Steven D. Wittlin MD
Associate Professor of Medicine
Clinical Director, Endocrine-Metabolism Division
University of Rochester School of Medicine and Dentistry
Strong Memorial Medical Center
Rochester, New York

Faculty Disclosures:

In the past 12 months, Dr. Wittlin reports receiving research support from Tolerx,Eli Lilly, Sanofi-Aventis, and. Biodel. He has been a consultant to Medtronics-MiniMed, and he has been on the Speaker's Bureau of Sanofi-Aventis, and Medtronics-Minimed. He has received speaking honoraria from Quest Diagnostics, Animas, and Biomarkers.

Educational Objectives:

Physicians, pharmacists, and other healthcare providers will:

• Learn how to use biomarkers in diabetes to improve patient care
• Learn how to monitor and measure postprandial glycemia in order tooptimize treatment of patients with diabetes
• Learn how to use novel biomarkers, including serum 1,5-Anhydroglucitolin order to reduce postprandial hyperglycemia and achieve HgbA1c level target goals

Disclaimer:

Copyright © 2008 by Pharmatecture, LLC. All rights reserved. Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this HealthWRAP reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this HealthWRAP is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this HealthWRAP is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This HealthWRAP is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This HealthWRAP is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright (c) 2007 All rights reserved